ClinicalTrials.Veeva

Menu

Safety and Efficacy of Remote Ischemic Conditioning in Patients with Severe Stenosis or Occlusion of Anterior Intracranial Circulation Vessels (RICASO)

U

University of Science and Technology of China (USTC)

Status

Not yet enrolling

Conditions

Acute Ischemic Stroke

Treatments

Device: RIC
Other: Guideline-based therapy
Device: Sham

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The primary purpose of this study is to examine whether remote ischemic treatment can better the 90 - day neurological outcomes in acute ischemic stroke patients having severe stenosis or occlusion of anterior intracranial circulation vessels.

Enrollment

1,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age is 18 years old or above.
  2. Severe stenosis (70% - 99%) or occlusion of anterior intracranial circulation vessels, mainly including the intracranial segment of the internal carotid artery, middle cerebral artery (M1, M2) and anterior cerebral artery (A1, A2), which is confirmed by digital subtraction angiography (DSA), computed tomography angiography (CTA) or magnetic resonance angiography (MRA).
  3. Patients with clinically diagnosed acute ischemic stroke who received remote ischemic treatment within 72 hours after the onset.
  4. The NIHSS score ranges from 4 to 24.
  5. The mRS score before stroke is less than or equal to 1.
  6. informed consent.

Exclusion criteria

  1. Patients with vessel recanalization after mechanical thrombectomy (TICI grade ≥ 2b).
  2. Patients planning to receive intracranial endovascular treatment within 3 months.
  3. Patients with cardiogenic embolism considered as the cause, such as rheumatic mitral or aortic valve stenosis, artificial heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, left ventricular wall thrombus or valvular vegetations, congestive heart failure, bacterial endocarditis, etc.
  4. Patients diagnosed with acute posterior circulation cerebral infarction.
  5. Symptoms caused by non - culprit vessels.
  6. Ipsilateral extracranial vessel stenosis ≥ 70%.
  7. Systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg, and uncontrollable by antihypertensive drugs.
  8. Intracranial tumors, arteriovenous malformations or aneurysms.
  9. Cerebral venous thrombosis or stenosis.
  10. Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural) within 90 days before enrollment.
  11. Severe coagulation abnormalities.
  12. Any contraindications to remote ischemic conditioning: severe soft tissue injury, fracture or vascular injury of the upper limb, perivascular lesions of the distal upper limb, etc.
  13. Patients with any serious diseases and a life expectancy of less than 1 year.
  14. Patients who participated in other clinical trials within 3 months before enrollment or are currently participating in other clinical trials.
  15. Patients who cannot be followed up (such as those without a fixed residence, overseas patients, etc.).
  16. Pregnant or lactating women.
  17. Patients who have previously received remote ischemic treatment or similar treatments.
  18. Patients whom the researchers consider unsuitable for this clinical study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

1,000 participants in 2 patient groups

RIC group+Guideline-based therapy
Experimental group
Description:
RIC is given twice a day with 200mmHg pressure.
Treatment:
Other: Guideline-based therapy
Device: RIC
Sham group+Guideline-based therapy
Active Comparator group
Description:
RIC is given twice a day with 60mmHg pressure.
Treatment:
Device: Sham
Other: Guideline-based therapy

Trial contacts and locations

1

Loading...

Central trial contact

Wei Hu, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems